Your browser is no longer supported. Please, upgrade your browser.
Baxter International Inc.
IndexS&P 500 P/E39.18 EPS (ttm)2.07 Insider Own0.20% Shs Outstand505.00M Perf Week-0.34%
Market Cap40.62B Forward P/E20.21 EPS next Y4.01 Insider Trans-2.05% Shs Float501.98M Perf Month0.26%
Income1.07B PEG3.41 EPS next Q0.75 Inst Own88.80% Short Float1.62% Perf Quarter-7.66%
Sales11.82B P/S3.44 EPS this Y37.10% Inst Trans0.21% Short Ratio3.14 Perf Half Y2.05%
Book/sh16.74 P/B4.85 EPS next Y14.26% ROA5.40% Target Price94.00 Perf Year-9.33%
Cash/sh6.36 P/C12.77 EPS next 5Y11.49% ROE12.60% 52W Range74.79 - 91.45 Perf YTD1.12%
Dividend1.12 P/FCF52.21 EPS past 5Y24.40% ROI8.60% 52W High-11.27% Beta0.67
Dividend %1.38% Quick Ratio1.80 Sales past 5Y3.20% Gross Margin39.20% 52W Low8.49% ATR1.04
Employees50000 Current Ratio2.50 Sales Q/Q5.10% Oper. Margin12.20% RSI (14)49.13 Volatility1.45% 1.28%
OptionableYes Debt/Eq0.72 EPS Q/Q-9.40% Profit Margin9.00% Rel Volume0.71 Prev Close80.51
ShortableYes LT Debt/Eq0.67 Earnings- Payout46.70% Avg Volume2.59M Price81.14
Recom2.20 SMA200.02% SMA50-0.80% SMA2000.34% Volume1,826,709 Change0.78%
May-25-21Initiated Barclays Equal Weight $93
Jan-29-21Downgrade Piper Sandler Overweight → Neutral $100 → $80
Jan-06-21Downgrade UBS Buy → Neutral $95 → $85
Dec-15-20Downgrade Goldman Buy → Neutral $96 → $85
Oct-01-20Upgrade Citigroup Neutral → Buy $94
Sep-04-20Downgrade Argus Buy → Hold
Jun-24-20Initiated Oppenheimer Outperform $100
Mar-19-20Upgrade Stifel Hold → Buy $87 → $95
Mar-18-20Upgrade KeyBanc Capital Markets Sector Weight → Overweight $92
Mar-05-20Initiated Citigroup Neutral $94
Feb-13-20Initiated Goldman Buy $104
Jan-02-20Upgrade Evercore ISI In-line → Outperform $80 → $94
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $90 → $88
Jun-26-19Initiated KeyBanc Capital Markets Sector Weight
Apr-08-19Downgrade Evercore ISI Outperform → In-line
Jan-02-19Upgrade Morgan Stanley Underweight → Overweight
Jan-02-19Upgrade Citigroup Neutral → Buy
Nov-02-18Upgrade Argus Hold → Buy
Oct-16-18Initiated Barclays Underweight $73
May-17-18Resumed Piper Jaffray Overweight $77
Jul-23-21 07:53AM  
Jul-22-21 03:03PM  
Jul-15-21 08:00AM  
Jul-12-21 06:30PM  
Jul-09-21 10:13AM  
Jul-08-21 09:06AM  
Jul-07-21 09:02AM  
Jul-06-21 08:53AM  
Jun-29-21 09:57AM  
Jun-28-21 10:13AM  
Jun-24-21 04:48PM  
Jun-15-21 04:15PM  
Jun-09-21 10:30AM  
Jun-08-21 08:30AM  
Jun-07-21 08:11AM  
Jun-02-21 08:30AM  
Jun-01-21 08:45AM  
May-29-21 03:13AM  
May-25-21 08:00AM  
May-20-21 06:23PM  
May-17-21 02:22AM  
May-10-21 04:44PM  
May-08-21 07:30AM  
May-04-21 04:15PM  
May-03-21 05:00PM  
Apr-29-21 01:00PM  
Apr-28-21 09:13AM  
Apr-26-21 12:10PM  
Apr-22-21 12:33PM  
Apr-21-21 09:45AM  
Apr-17-21 03:43AM  
Apr-12-21 03:58PM  
Apr-07-21 04:15PM  
Mar-30-21 04:15PM  
Mar-29-21 03:55PM  
Mar-24-21 04:15PM  
Mar-18-21 01:50AM  
Mar-16-21 08:56AM  
Mar-12-21 08:00AM  
Mar-10-21 04:15PM  
Mar-08-21 09:46AM  
Mar-06-21 11:31AM  
Feb-26-21 05:07PM  
Feb-20-21 02:11AM  
Feb-18-21 01:09AM  
Feb-16-21 04:30PM  
Feb-04-21 07:00PM  
Feb-01-21 09:43AM  
Jan-28-21 12:32PM  
Jan-23-21 01:41AM  
Jan-21-21 04:15PM  
Jan-12-21 09:09AM  
Jan-11-21 08:30AM  
Jan-05-21 04:15PM  
Dec-23-20 11:32PM  
Dec-16-20 04:15PM  
Dec-09-20 11:55AM  
Dec-08-20 05:56PM  
Dec-07-20 08:05AM  
Dec-06-20 11:45AM  
Dec-03-20 08:00AM  
Dec-01-20 03:48PM  
Nov-30-20 01:44PM  
Nov-28-20 01:29AM  
Nov-27-20 12:00AM  
Nov-26-20 07:15AM  
Nov-24-20 08:00AM  
Nov-23-20 08:00AM  
Nov-18-20 04:15PM  
Nov-17-20 04:47PM  
Nov-16-20 04:15PM  
Nov-12-20 08:46AM  
Nov-11-20 08:11AM  
Nov-01-20 07:34AM  
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frye AndrewSVP, President, APACApr 12Sale84.7910,999932,6059,041Apr 14 04:04 PM
HELLMAN PETER SDirectorApr 05Option Exercise31.264,990155,98730,389Apr 07 06:55 PM
STROUCKEN ALBERT P LDirectorApr 05Option Exercise31.264,990155,98736,886Apr 07 06:57 PM
STROUCKEN ALBERT P LDirectorApr 05Sale84.564,990421,95431,896Apr 07 06:57 PM
HELLMAN PETER SDirectorApr 05Sale84.564,990421,95425,399Apr 07 06:55 PM
Martin SeanSVP and General CounselNov 02Option Exercise50.7747,0012,386,24186,641Nov 04 04:05 PM
Martin SeanSVP and General CounselNov 02Sale78.6747,0013,697,79439,640Nov 04 04:05 PM
FORSYTH JOHN DDirectorSep 14Option Exercise31.263109,69134,279Sep 15 04:07 PM
FORSYTH JOHN DDirectorSep 14Sale83.5931025,91333,969Sep 15 04:07 PM
GAVIN JAMES R IIIDirectorAug 03Option Exercise38.1414,899568,28954,407Aug 05 05:39 PM
GAVIN JAMES R IIIDirectorAug 03Sale86.4114,8991,287,36639,508Aug 05 05:39 PM